American Technology Research Initiates Coverage On Pfizer (PFE) With A Buy
More News related to PFE
- Beacon Equity Issues Technical Trade Alerts on Drug Manufacturers: NVS, JNJ, PFE, GSK, ABT, AZN
- Pfizer Withdraws Application to Switch Viagra to Non-Prescription Status in Europe
- Quarterly Data Confirms Hedge Funds Exited Stocks In A Big Way
- Pacific Energy Resources Ltd. Announces Third Quarter 2008 Operating and Financial Results
- Pacific Energy Resources Ltd. Announces Third Quarter 2008 Operating and Financial Results
More News related to Analyst Comments
- Merrill Smacks Down the REIT Space: Downgrades 29 Stocks, Upgrades 2
- Solars Rise as Merrill Downgrades First Solar (FSLR), SunPower (SPWRA)
- Merrill Lynch Downgrades Autodesk (ADSK) to Underperform
- Friedman Billings Downgrades Goodrich (GR) to Market Perform
- Friedman Billings Downgrades Spirit AeroSystems (SPR) to Market Perform
Today, American Technology Research initiates coverage on Pfizer (NYSE: PFE) with a Buy and a $24 price target, which is 34% upside from here.
Am Tech said following last week's patent settlement with Ranbaxy Labs on
Lipitor, extending the franchise to end of 2011, AmTech has increased confidence in Pfizer's ability to fund its 7.1% dividend and an extended share buy-back program. Am Tech also said it believes Pfizer will support its late-stage R&D efforts, and seek acquisition opportunities to help lessen the Lipitor fall off in 2012.
Am Tech believes Pfizer is significantly undervalued and will likely rise from here.
Pfizer Inc. is a research-based, global pharmaceutical company.
Related Categories
Analyst CommentsInsiders' Blog
Stocks Mentioned
+0.47Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
